Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-FXX489
- Development stage
- Phase 1
- Lead developer
- Yi Tian
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-FXX489, also known as NNS309, is a radiopharmaceutical diagnostic agent developed for Positron Emission Tomography (PET/CT) imaging. It is a Gallium-68 labeled radiotracer that specifically targets Fibroblast Activation Protein (FAP), a type II transmembrane serine protease that is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of various solid tumors. Because FAP expression is minimal in most healthy adult tissues, 68Ga-FXX489 provides high-contrast imaging of the tumor microenvironment, facilitating the diagnosis, staging, and monitoring of oncological diseases. The agent is currently being evaluated in clinical trials sponsored by Yi Tian to assess its safety, biodistribution, and diagnostic performance compared to other FAP-targeting tracers.
- Other names
- Gallium-68 FXX489Gallium68 FXX489Gallium 68 FXX48968Ga-FXX489 (NNS309)
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-FXX489.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-FXX489.